ERBB2 and central nervous system cancer: Based on these findings, the National Comprehensive Cancer Network® (NCCN®) recently added pertuzumab plus high-dose trastuzumab as a category 2A regimen for patients with HER2-positive MBC and brain metastases (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2023.